Die Perspektive der Privaten Krankenversicherung bei der Bewertung von Ressourcenverbräuchen im Rahmen von gesundheitsökonomischen Evaluationen: Sinnhaftigkeit und Umsetzung

Publikation: Beitrag in FachzeitschriftÜbersichtsarbeitForschungPeer-Review

Autoren

  • A. Lange
  • A. Prenzler
  • J. M. Graf Von Der Schulenburg

Organisationseinheiten

Forschungs-netzwerk anzeigen

Details

Titel in ÜbersetzungThe perspective of the private health insurance in Germany for health economic evaluations: Sense and realization
OriginalspracheDeutsch
Seiten (von - bis)185-191
Seitenumfang7
FachzeitschriftGesundheitsokonomie und Qualitatsmanagement
Jahrgang17
Ausgabenummer4
Frühes Online-Datum5 Jan. 2012
PublikationsstatusVeröffentlicht - Aug. 2012

Abstract

At first this paper discusses under which conditions a health economic evaluation from the perspective of the Private Health Insurance (PHI) seems reasonable. Subsequent, a systematic overview of relevant resource use as well as its valuation from the perspective of the PHI is given. This includes all relevant cost domains from ambulatory and inpatient care as well as a detailed description of relevant data resulting from drug usage. For prescriptions the legal framework (e. g., reference pricing) is applied to list all relevant co-payments or discounts (e. g., for pharmaceutical companies) which have to be considered in patented as well as off-patent drugs. For ambulatory services the medical fee schedule should be considered. Regarding inpatient stays, general hospital services as well as treatment by chief physician and special accommodation have to be taken into account. As a result, for the first time, a pragmatic as well as a practical approach is presented to value resource usage within the German health care system in future studies from the perspective of the private health insurance.

Schlagwörter

    cost analyses, costs, Germany, methods, perspective, Private Health Insurance

ASJC Scopus Sachgebiete

Ziele für nachhaltige Entwicklung

Zitieren

Die Perspektive der Privaten Krankenversicherung bei der Bewertung von Ressourcenverbräuchen im Rahmen von gesundheitsökonomischen Evaluationen: Sinnhaftigkeit und Umsetzung. / Lange, A.; Prenzler, A.; Graf Von Der Schulenburg, J. M.
in: Gesundheitsokonomie und Qualitatsmanagement, Jahrgang 17, Nr. 4, 08.2012, S. 185-191.

Publikation: Beitrag in FachzeitschriftÜbersichtsarbeitForschungPeer-Review

Lange A, Prenzler A, Graf Von Der Schulenburg JM. Die Perspektive der Privaten Krankenversicherung bei der Bewertung von Ressourcenverbräuchen im Rahmen von gesundheitsökonomischen Evaluationen: Sinnhaftigkeit und Umsetzung. Gesundheitsokonomie und Qualitatsmanagement. 2012 Aug;17(4):185-191. Epub 2012 Jan 5. doi: 10.1055/s-0031-1282020
Lange, A. ; Prenzler, A. ; Graf Von Der Schulenburg, J. M. / Die Perspektive der Privaten Krankenversicherung bei der Bewertung von Ressourcenverbräuchen im Rahmen von gesundheitsökonomischen Evaluationen : Sinnhaftigkeit und Umsetzung. in: Gesundheitsokonomie und Qualitatsmanagement. 2012 ; Jahrgang 17, Nr. 4. S. 185-191.
Download
@article{afa9eecc279a4805ac0300528a726855,
title = "Die Perspektive der Privaten Krankenversicherung bei der Bewertung von Ressourcenverbr{\"a}uchen im Rahmen von gesundheits{\"o}konomischen Evaluationen: Sinnhaftigkeit und Umsetzung",
abstract = "At first this paper discusses under which conditions a health economic evaluation from the perspective of the Private Health Insurance (PHI) seems reasonable. Subsequent, a systematic overview of relevant resource use as well as its valuation from the perspective of the PHI is given. This includes all relevant cost domains from ambulatory and inpatient care as well as a detailed description of relevant data resulting from drug usage. For prescriptions the legal framework (e. g., reference pricing) is applied to list all relevant co-payments or discounts (e. g., for pharmaceutical companies) which have to be considered in patented as well as off-patent drugs. For ambulatory services the medical fee schedule should be considered. Regarding inpatient stays, general hospital services as well as treatment by chief physician and special accommodation have to be taken into account. As a result, for the first time, a pragmatic as well as a practical approach is presented to value resource usage within the German health care system in future studies from the perspective of the private health insurance.",
keywords = "cost analyses, costs, Germany, methods, perspective, Private Health Insurance",
author = "A. Lange and A. Prenzler and {Graf Von Der Schulenburg}, {J. M.}",
year = "2012",
month = aug,
doi = "10.1055/s-0031-1282020",
language = "Deutsch",
volume = "17",
pages = "185--191",
number = "4",

}

Download

TY - JOUR

T1 - Die Perspektive der Privaten Krankenversicherung bei der Bewertung von Ressourcenverbräuchen im Rahmen von gesundheitsökonomischen Evaluationen

T2 - Sinnhaftigkeit und Umsetzung

AU - Lange, A.

AU - Prenzler, A.

AU - Graf Von Der Schulenburg, J. M.

PY - 2012/8

Y1 - 2012/8

N2 - At first this paper discusses under which conditions a health economic evaluation from the perspective of the Private Health Insurance (PHI) seems reasonable. Subsequent, a systematic overview of relevant resource use as well as its valuation from the perspective of the PHI is given. This includes all relevant cost domains from ambulatory and inpatient care as well as a detailed description of relevant data resulting from drug usage. For prescriptions the legal framework (e. g., reference pricing) is applied to list all relevant co-payments or discounts (e. g., for pharmaceutical companies) which have to be considered in patented as well as off-patent drugs. For ambulatory services the medical fee schedule should be considered. Regarding inpatient stays, general hospital services as well as treatment by chief physician and special accommodation have to be taken into account. As a result, for the first time, a pragmatic as well as a practical approach is presented to value resource usage within the German health care system in future studies from the perspective of the private health insurance.

AB - At first this paper discusses under which conditions a health economic evaluation from the perspective of the Private Health Insurance (PHI) seems reasonable. Subsequent, a systematic overview of relevant resource use as well as its valuation from the perspective of the PHI is given. This includes all relevant cost domains from ambulatory and inpatient care as well as a detailed description of relevant data resulting from drug usage. For prescriptions the legal framework (e. g., reference pricing) is applied to list all relevant co-payments or discounts (e. g., for pharmaceutical companies) which have to be considered in patented as well as off-patent drugs. For ambulatory services the medical fee schedule should be considered. Regarding inpatient stays, general hospital services as well as treatment by chief physician and special accommodation have to be taken into account. As a result, for the first time, a pragmatic as well as a practical approach is presented to value resource usage within the German health care system in future studies from the perspective of the private health insurance.

KW - cost analyses

KW - costs

KW - Germany

KW - methods

KW - perspective

KW - Private Health Insurance

UR - http://www.scopus.com/inward/record.url?scp=84865468149&partnerID=8YFLogxK

U2 - 10.1055/s-0031-1282020

DO - 10.1055/s-0031-1282020

M3 - Übersichtsarbeit

AN - SCOPUS:84865468149

VL - 17

SP - 185

EP - 191

JO - Gesundheitsokonomie und Qualitatsmanagement

JF - Gesundheitsokonomie und Qualitatsmanagement

SN - 1432-2625

IS - 4

ER -